Cargando…

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are caused by the constitutive activation of KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations. Imatinib selectively inhibits KIT and PDGFR, leading to disease control for 80%–90% of patients with metastatic GIST. Imatinib res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeh, Chun-Nan, Chen, Ming-Huang, Chen, Yen-Yang, Yang, Ching-Yao, Yen, Chueh-Chuan, Tzen, Chin-Yuan, Chen, Li-Tzong, Chen, Jen-Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546467/ https://www.ncbi.nlm.nih.gov/pubmed/28487491 http://dx.doi.org/10.18632/oncotarget.17310

Ejemplares similares

Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors
por: Chen, Jen-Shi, et al.
Publicado: (2018)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Unresectable gastrointestinal stromal tumors
por: Menon, Prema, et al.
Publicado: (2011)

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2014)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
por: Koo, Dong-Hoe, et al.
Publicado: (2016)

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
por: Yeh, Chun-Nan, et al.
Publicado: (2014)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours
por: Foo, Tiffany, et al.
Publicado: (2022)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib
por: Fujimi, Akihito, et al.
Publicado: (2019)

Whole-genome and Epigenomic Landscapes of Malignant Gastrointestinal Stromal Tumors Harboring KIT Exon 11 557–558 Deletion Mutations
por: Ohshima, Keiichi, et al.
Publicado: (2023)

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View
por: Wu, Chiao-En, et al.
Publicado: (2019)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
por: Kollàr, Attila, et al.
Publicado: (2014)

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
por: Ichinose, Yuichi, et al.
Publicado: (2022)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer
por: Xu, Huanji, et al.
Publicado: (2020)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
por: Han, Yue, et al.
Publicado: (2021)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
por: Kato, Takeshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jredfdl26hl704tcf3lptpmgas